soul trial oral semaglutide cardiovascular outcomes 2024 nejm results Editorial Fellow Harleen Marwah, MD, summarizes the trial. Read the full at NEJM.org (link in bio). ⁣ ⁣ #ACC25 #Cardiology #ClinicalTrials #NEJM Oral Semaglutide's Impact on Cardiovascular

(3) Intervention Timing: clear delineation of preventive/co-treatment paradigms versus therapeutic paradigms

503(b) compounding pharmacies can produce large batches of compounded drugs during shortages, operating under FDA oversight that permits this production when commercially available alternatives do not exist

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has garnered significant attention for its effectiveness in managing type 2 diabetes and promoting weight loss

PEGylation the conjugation of polyethylene glycol chains to the peptide extends this half-life substantially, to several hours, enabling stable receptor engagement over experimental time windows that native MGF cannot sustain